Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
liposome paclitaxel
DRUG
2 trials
Sponsors
Xi'an Jiaotong University
, Tianjin Medical University Cancer Institute and Hospital
Conditions
Cervical Cancer
First-line Treatment
Non-small Cell Lung Cancer
Phase 1
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
NCT03987867
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Non-small Cell Lung Cancer
Start: 2019-06-01
End: 2021-06-01
Target: 30
Updated: 2020-07-07
Phase 2
Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women
NCT01594099
Xi'an Jiaotong University
Cervical Cancer
Start: 2012-04-30
End: 2014-03-31
Target: 45
Updated: 2012-05-08
Related Papers
Long-term outcome for patients with advanced non‒small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.
Journal of Clinical Oncology
2023-06-01
1 citations
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer
2022-07-21
35 citations
A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002.
Journal of Clinical Oncology
2021-05-20
2 citations